Novo Nordisk A/S Reports that CagriSema Achieved a 1.91-percentage-point HbA1c Reduction and 14.2% Weight Loss in Adults with Type 2 Diabetes in the REIMAGINE 2 Study
Novo Nordisk announced top-line findings from REIMAGINE 2, a phase 3 study within the global REIMAGINE programme. The results show that CagriSema achieved greater reductions in HbA1c and greater weight loss at week 68 than semaglutide across all tested doses.
REIMAGINE 2 was a 68-week trial assessing the efficacy and safety of once-weekly subcutaneous CagriSema, a fixed-dose combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide, at two dose levels (2.4 m...